Diffuse Optical Tomography (DOT) for Monitoring Response to Neoadjuvant (Preoperative) Chemotherapy in Breast Cancer
The pilot study will enrol up to ten patients over one year. Patients receiving neoadjuvant
chemotherapy for breast cancer will undergo baseline clinical examination, mammography,
ultrasound, MRI and DOT before commencement of treatment. DOT will be repeated at 1,3,6
weeks after chemotherapy, and at the end of each chemotherapy regimen. Ultrasound will be
repeated every 6 weeks and at the end of treatment. Mammography and MRI will be repeated
once at the end of treatment before surgery. A breast pathologist will evaluate the subtype
of breast cancer and the pathologic response of the operative specimen at the end of
treatment. Patient satisfaction questionnaires will be administered to evaluate their
preferences for DOT, ultrasound, mammography and MRI scanning at the beginning and the end
of the study.
Observational
Observational Model: Cohort, Time Perspective: Prospective
Parameters derived from the optical images acquired with the DOT system
The primary parameters derived from the optical images acquired with the DOT system include: The volume of tumor microvasculature V, the total haemoglobin concentration (THC), and the blood volume index BVI (=VC). Other available optical parameters are: blood oxygenation in the tumor microvasculature (SO2), its spatial distribution and dynamic fluctuation; dynamic blood perfusion. These parameters will be compared with histopathological response.
These parameters will be obtained from patients during neoadjuvant chemotherapy process, which is up to an average of 6 months
No
Yoon Sim Yap, MBBS, FRACP
Principal Investigator
National Cancer Centre, Singapore
Singapore: SingHealth Centralised Institutional Review Board
11-7-BRE
NCT01394315
August 2011
May 2013
Name | Location |
---|